News Positive phase 3 results for Zealand Pharma's glepaglutide Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
